S
S K Spangler
Researcher at Penn State Milton S. Hershey Medical Center
Publications - 47
Citations - 1599
S K Spangler is an academic researcher from Penn State Milton S. Hershey Medical Center. The author has contributed to research in topics: Cefoxitin & Penicillin. The author has an hindex of 24, co-authored 47 publications receiving 1577 citations. Previous affiliations of S K Spangler include Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
TL;DR: Although beta-lactamase positivity is on the increase in non-B.
Journal ArticleDOI
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
TL;DR: Agar dilution was used to compare the in vitro activity of CP 99,219 with those of ciprofloxacins, grepafloxacin, metronidazole, cefoxitin, piperacillin, and pipersacillin-tazobactam against 489 anaerobes.
Journal ArticleDOI
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
TL;DR: All four experimental quinolones as well as RP 59500 show promise for therapy of infections with penicillin-resistant and -susceptible pneumococci.
Journal ArticleDOI
Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
TL;DR: The in vitro activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with six beta-Lactams with significantly greater activity than that of the Beta- lactams alone against all groups except B. fragilis homology group II.
Journal ArticleDOI
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
TL;DR: The MICs of RPR 106972, cefditoren, two new oxazolidinones, and other oral and parenteral agents for 203 penicillin-susceptible and -resistant pneumococci were determined.